The Animal Micro-Volume Intranasal Atomization Device is designed for precise intranasal administration to mice and rats. Nasal pharmaceutical formulations act locally or systemically, with key strengths including fast absorption, circumvention of hepatic first-pass effect, elevated bioavailability, and nose-to-brain drug targeting that bypasses the blood-brain barrier. The aerosol quality of nasal formulations is a critical quality attribute directly linked to drug efficacy and safety.
With rodents fixed on a restraining platform, this system administers accurately quantified liquid samples into the nasal cavity. It achieves more uniform nasal distribution and superior deposition in deep nasal and olfactory regions relative to conventional nasal instillation. The system safely delivers high-concentration formulations, supporting drug solutions, homogeneous suspensions, small-cell suspensions and low-viscosity emulsions. It serves research covering nose-to-brain targeting, nasal formulation development, pharmacology & toxicology, mucosal immunity, nasal vaccine research and fundamental delivery mechanism studies.
Intranasal preparations exert local or systemic therapeutic effects after nasal administration. They offer multiple advantages: rapid absorption, fast onset of action, avoidance of hepatic first-pass metabolism, high bioavailability, and nose-to-brain targeting by bypassing the blood‑brain barrier. The aerosol characteristics of atomized formulations represent a critical quality attribute that directly determines drug efficacy and safety.
When mice or rats are secured on the restraining platform, this delivery device administers precisely metered liquid test articles into the rodent nasal cavity for intranasal research.
